User Image Cart Icon 0 Search Image

Thiazolidinediones

  1. Thiazolidinediones
  2. Nonhypoglycemic effects of thiazolidinediones
  3. Thiazolidinediones
  4. Thiazolidinediones: an update
  5. The mode of action of thiazolidinediones
  6. Metabolic and additional vascular effects of thiazolidinediones
  7. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
  8. How safe is the use of thiazolidinediones in clinical practice?
  9. Unraveling the mechanism of action of thiazolidinediones
  10. Insulin resistance and its treatment by thiazolidinediones.
  11. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors
  12. Use of thiazolidinediones and fracture risk
  13. Thiazolidinediones as anti-cancer agents
  14. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence
  15. Effect of thiazolidinediones on body weight in patients with diabetes mellitus
  16. Thiazolidinediones and fractures in men and women
  17. Thiazolidinediones: a new class of antidiabetic drugs
  18. Thiazolidinediones and liver toxicity.
  19. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside
  20. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
  21. Thiazolidinediones: a 2010 perspective
  22. Thiazolidinediones: effects on insulin resistance and the cardiovascular system
  23. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes
  24. Pleiotropic effects of thiazolidinediones
  25. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones
  26. Hepatotoxicity with thiazolidinediones: is it a class effect?
  27. Hepatotoxicity of the thiazolidinediones
  28. Thiazolidinediones-mechanisms of action
  29. Thiazolidinediones and blood lipids in type 2 diabetes
  30. Thiazolidinediones and heart failure: a teleo-analysis
  31. Thiazolidinediones: metabolic actions in vitro
  32. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes
  33. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects
  34. Thiazolidinediones and inflammation
  35. Mechanisms by which thiazolidinediones enhance insulin action
  36. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
  37. The safety of thiazolidinediones
  38. Considerations for management of fluid dynamic issues associated with thiazolidinediones
  39. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis
  40. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study
  41. Hepatotoxicity of thiazolidinediones
  42. Thiazolidinediones and the risk of edema: a meta-analysis
  43. Thiazolidinediones: a comparative review of approved uses
  44. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
  45. Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells
  46. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications
  47. Thiazolidinediones improve β-cell function in type 2 diabetic patients
  48. The effect of thiazolidinediones on BMD and osteoporosis
  49. Thiazolidinediones for the treatment of type 2 diabetes
  50. Visfatin is an adipokine, but it is not regulated by thiazolidinediones
  51. Pharmacokinetic interactions with thiazolidinediones
  52. Thiazolidinediones and fractures: evidence from translating research into action for diabetes
  53. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones
  54. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling.
  55. Thiazolidinediones as anti‐inflammatory and anti‐atherogenic agents
  56. Thiazolidinediones: the case for early use
  57. PPARγ-independent antitumor effects of thiazolidinediones
  58. The role of thiazolidinediones in non-alcoholic steatohepatitis–a systematic review and meta analysis
  59. New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications
  60. Thiazolidinediones–some recent developments
  61. Thiazolidinediones, insulin resistance and obesity: finding a balance
  62. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity
  63. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues
  64. Mechanisms and clinical effects of thiazolidinediones
  65. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real‐life experience from a tertiary hospital
  66. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes.
  67. Thiazolidinediones: a plethro of biological load
  68. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study
  69. Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones
  70. Effects of thiazolidinediones on bone loss and fracture
  71. Second-generation thiazolidinediones and hepatotoxicity
  72. Recent findings concerning thiazolidinediones in the treatment of diabetes
  73. Thiazolidinediones and heart failure
  74. Thiazolidinediones and the liver in humans
  75. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis
  76. Thiazolidinediones today
  77. Effects of thiazolidinediones on differentiation, proliferation, and apoptosis
  78. A meta‐analysis of the effect of thiazolidinediones on blood pressure
  79. Effects of thiazolidinediones and sulfonylureas in patients with diabetes
  80. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?
  81. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients
  82. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro
  83. Therapeutic potential of thiazolidinediones as anticancer agents
  84. Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells
  85. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition
  86. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma.
  87. Redefining the role of thiazolidinediones in the management of type 2 diabetes
  88. The effect of thiazolidinediones on adiponectin serum level: a meta‐analysis
  89. The Structure− Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones
  90. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes
  91. Brain PPAR-γ promotes obesity and is required for the insulin–sensitizing effect of thiazolidinediones
  92. Thiazolidinediones and type 2 diabetes: new drugs for an old disease
  93. Thiazolidinediones and cardiovascular risk—a question of balance
  94. Reassessing the cardiovascular risks and benefits of thiazolidinediones
  95. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice
  96. Thiazolidinediones regulate adipose lineage dynamics
  97. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System
  98. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle–dependent mechanisms
  99. Thiazolidinediones and fracture risk in patients with type 2 diabetes
  100. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus
  101. Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes
  102. A cohort study of thiazolidinediones and fractures in older adults with diabetes
  103. Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption
  104. Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells
  105. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study
  106. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.
  107. Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones
  108. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
  109. Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers
  110. Thiazolidinediones in diabetes: current status and future outlook.
  111. Recent thiazolidinediones as antidiabetics
  112. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic …
  113. Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs
  114. The effects of thiazolidinediones on blood pressure levels–a systematic review
  115. Effects of thiazolidinediones on stroke recovery: a case-matched controlled study
  116. Effects of thiazolidinediones beyond glycaemic control
  117. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality
  118. Diabetic KKAy mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones
  119. Down regulation of peroxisome proliferator-activated receptorγ expression by inflammatory cytokines and its reversal by thiazolidinediones
  120. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation
  121. Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects
  122. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products
  123. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients
  124. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability
  125. Trans-differentiation of myoblasts to adipoblasts: triggering effects of fatty acids and thiazolidinediones
  126. Mechanisms of action of thiazolidinediones
  127. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones
  128. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture
  129. Thiazolidinediones and glucocorticoids synergistically induce differentiation of human adipose tissue stromal cells: biochemical, cellular, and molecular analysis
  130. Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study
  131. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact
  132. Thiazolidinediones in dermatology
  133. Thiazolidinediones and insulin resistance: Peroxisome proliferatoractivated receptor γ activation stimulates expression of the CAP gene
  134. Synthesis and biological activity of novel acridinylidene and benzylidene thiazolidinediones
  135. Structure–activity relationships and molecular modelling of 5-arylidene-2, 4-thiazolidinediones active as aldose reductase inhibitors
  136. Synthesis and biological activity of novel thiazolidinediones
  137. Energy restriction as an antitumor target of thiazolidinediones
  138. Discovery of 5-aryloxy-2, 4-thiazolidinediones as potent GPR40 agonists
  139. Cardiovascular risk and thiazolidinediones—what do meta‐analyses really tell us?
  140. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions …
  141. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents
  142. Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents
  143. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo …
  144. The preventive anti‐oxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance
  145. β-cell preservation with thiazolidinediones
  146. Effects of thiazolidinediones on blood pressure
  147. Thiazolidinediones for initial treatment of type 2 diabetes?
  148. Response of experimental retinal neovascularization to thiazolidinediones
  149. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones
  150. Thiazolidinediones for treatment of polycystic ovary syndrome
  151. Beyond peroxisome proliferator-activated receptor γ signaling: the multi-facets of the antitumor effect of thiazolidinediones
  152. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability
  153. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients
  154. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies
  155. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus
  156. Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway
  157. Progress with thiazolidinediones in the management of type 2 diabetes mellitus
  158. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3β-hydroxysteroid dehydrogenase
  159. Thiazolidinediones as therapy for endometriosis: a case series
  160. Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells
  161. A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells
  162. Thiazolidinediones on PPARγ: The Roles in Bone Remodeling
  163. Thiazolidinediones and fertility in polycystic ovary syndrome (PCOS)
  164. A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications
  165. Thiazolidinediones in the treatment of type 2 diabetes
  166. A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone
  167. The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus
  168. Synthesis, characterization and antimicrobial activity evaluation of new 2, 4-Thiazolidinediones bearing imidazo [2, 1-b][1, 3, 4] thiadiazole moiety
  169. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus
  170. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates
  171. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta‐analysis
  172. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones
  173. Thiazolidinediones and clinical outcomes in type 2 diabetes
  174. Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis
  175. β-Cell rejuvenation with thiazolidinediones
  176. Drug insight: thiazolidinediones and diabetic nephropathy—relevance to renoprotection
  177. the treatment of non‐alcoholic steatohepatitis with thiazolidinediones
  178. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanisms
  179. Addressing the insulin resistance syndrome: a role for the thiazolidinediones
  180. Peroxisome proliferator-activated receptor γ-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells
  181. Dual PPAR-α and-γ activators derived from novel benzoxazinone containing thiazolidinediones having antidiabetic and hypolipidemic potential
  182. Thiazolidinediones in type 2 diabetes: a cardiology perspective
  183. The potential of antidiabetic thiazolidinediones for anticancer therapy
  184. Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells
  185. Thiazolidinediones (PPARγ agonists) but not PPAR α agonists increase IRS‐2 gene expression in 3T3‐L1 and human adipocytes1
  186. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARγ on vascular endothelial function
  187. Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones
  188. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARγ in endothelial …
  189. The cardiovascular effects of the thiazolidinediones: a review of the clinical data
  190. Differential regulation of the stearoyl-CoA desaturase genes by thiazolidinediones in 3T3-L1 adipocytes
  191. Adiponectin gene activation by thiazolidinediones requires PPARγ2, but not C/EBPα—evidence for differential regulation of the aP2 and adiponectin genes
  192. Glucocorticoids and thiazolidinediones interfere with adipocyte-mediated macrophage chemotaxis and recruitment
  193. Thiazolidinediones: pleiotropic drugs with potent anti-inflammatory properties for tissue protection
  194. Thiazolidinediones are partial agonists for the glucocorticoid receptor
  195. Thiazolidinediones for nonalcoholic steatohepatitis—promising but not ready for prime time
  196. Pleiotropic effects of thiazolidinediones on traditional and non‐traditional atherosclerotic risk factors
  197. Thiazolidinediones Inhibit Osteoclast-Like Cell Formation and Bone Resorption in Vitro
  198. Role of PPAR-γ agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective
  199. Section review: oncologic, endocrine & metabolic: thiazolidinediones
  200. Effects of the thiazolidinediones on cardiovascular risk factors
  201. Thiazolidinediones: do harms outweigh benefits?
  202. Thiazolidinediones: a review of their benefits and risks
  203. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis
  204. Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression
  205. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R
  206. Anti-inflammatory effects of thiazolidinediones in human airway smooth muscle cells
  207. [[. omega.-(Heterocyclylamino) alkoxy] benzyl]-2, 4-thiazolidinediones as potent antihyperglycemic agents
  208. Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism
  209. Thiazolidinediones, peroxisome proliferator-activated receptor γ agonists, regulate endothelial cell growth and secretion of vasoactive peptides
  210. Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities
  211. The new clinical trials with thiazolidinediones–DREAM, ADOPT, and CHICAGO: promises fulfilled?
  212. Topical treatment with thiazolidinediones, activators of peroxisome proliferator‐activated receptor‐γ, normalizes epidermal homeostasis in a murine hyperproliferative …
  213. Impaired adipogenic response to thiazolidinediones in mice expressing human apolipoproteinE4
  214. Thiazolidinediones: beyond glycemic control
  215. Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model
  216. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in …
  217. Do thiazolidinediones cause heart failure? A critical review.
  218. Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?
  219. Thiazolidinediones: a pharmacological overview
  220. Thiazolidinediones inhibit TNFα induction of PAI-1 independent of PPARγ activation
  221. Thiazolidinediones inhibit the expression of beta3-adrenergic receptors at a transcriptional level.
  222. Cardiovascular effects of the thiazolidinediones
  223. β‐cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes
  224. Factors associated with results and conclusions of trials of thiazolidinediones
  225. Vascular reactivity and thiazolidinediones
  226. Thiazolidinediones and rexinoids induce peroxisome proliferator-activated receptor-coactivator (PGC)-1α gene transcription: an autoregulatory loop controls PGC-1α …
  227. The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages
  228. PPARγ activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFβ signalling
  229. Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre‐clinical systematic review
  230. Biguanides and thiazolidinediones inhibit stimulated lipolysis in human adipocytes through activation of AMP-activated protein kinase
  231. Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones
  232. The potential role of thiazolidinediones in atrial fibrillation
  233. A placebo‐controlled trial of exenatide twice‐daily added to thiazolidinediones alone or in combination with metformin
  234. Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration
  235. Antiatherogenic effects of thiazolidinediones?
  236. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy
  237. Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure
  238. Fluid retention with thiazolidinediones: does the mechanism influence the outcome?
  239. Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones
  240. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone
  241. Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects
  242. Pro-inflammatory properties for thiazolidinediones
  243. Thiazolidinediones and type 2 diabetes: from cellular targets to cardiovascular benefit
  244. Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis
  245. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus
  246. Thiazolidinediones: new evidence of bone loss
  247. Fracture risk a class effect of thiazolidinediones in women
  248. Pleiotropic actions of PPARg activators thiazolidinediones in cardiovascular diseases
  249. Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy?
  250. Acute and selective regulation of glyceroneogenesis and cytosolic phosphoenolpyruvate carboxykinase in adipose tissue by thiazolidinediones in type 2 …
  251. Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats
  252. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs)
  253. Thiazolidinediones stimulate uncoupling protein-2 expression in cell lines representing white and brown adipose tissues and skeletal muscle
  254. Thiazolidinediones downregulate stearoyl-CoA desaturase 1 gene expression in 3T3-L1 adipocytes
  255. Thiazolidinediones induce proliferation of human bronchial epithelial cells through the GPR40 receptor
  256. Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels
  257. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis
  258. Cardiovascular risk and the thiazolidinediones: déjà vu all over again?
  259. Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPARγ agonism
  260. Comparison of the antidiabetic effects of brain‐derived neurotrophic factor and thiazolidinediones in obese diabetic mice
  261. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473 000 patients using the National Health …
  262. Thiazolidinediones—benefits on microvascular complications of type 2 diabetes
  263. Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes
  264. Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARγ-dependent nongenomic signaling
  265. Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner
  266. Insulin sensitizing pharmacology of thiazolidinediones correlates with mitochondrial gene expression rather than activation of PPARγ
  267. Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin
  268. Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats
  269. Comparison of direct action of thiazolidinediones and glucocorticoids on renal podocytes: protection from injury and molecular effects
  270. Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro
  271. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications
  272. Thiazolidinediones-the new insulin enhancers
  273. Insulin resistance and the effects of thiazolidinediones on cardiac metabolism
  274. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer
  275. Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus
  276. Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes
  277. Thiazolidinediones: clinical data and perspectives
  278. Thiazolidinediones and their effects on glucose transporters
  279. Thiazolidinediones as a novel class of algicides against red tide harmful algal species
  280. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database
  281. Thiazolidinediones for the prevention of diabetes in the non‐obese diabetic (NOD) mouse: implications for human type 1 diabetes
  282. Thiazolidinediones and bone
  283. Hypoglycemic Action of Thiazolidinediones/Peroxisome Proliferator–Activated Receptor γ by Inhibition of the c-Jun NH2-Terminal Kinase Pathway
  284. Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of …
  285. A “futile cycle” induced by thiazolidinediones in human adipose tissue?
  286. Where thiazolidinediones will fit
  287. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism.
  288. The influence of thiazolidinediones on adipogenesis in vitro and in vivo: Potential modifiers of intramuscular adipose tissue deposition in meat animals,
  289. Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus–transgenic mice by peroxisome proliferator‐activated receptor γ–independent regulation of …
  290. Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data
  291. Leukopenia and thrombocytopenia caused by thiazolidinediones
  292. The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease
  293. Lipoprotein effects of different thiazolidinediones in clinical practice
  294. Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes
  295. Investigation of the lipophilic behaviour of some thiazolidinediones: Relationships with PPAR-γ activity
  296. Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARγ-dependent and PPARγ-independent pathways
  297. Rapid racemization in thiazolidinediones: a quantum chemical study
  298. Thiazolidinediones inhibit insulin-like growth factor-I–induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity
  299. Effect of thiazolidinediones on bile acid transport in rat liver
  300. Novel actions of thiazolidinediones on vascular function and exercise capacity
  301. Thiazolidinediones enhance skeletal muscle triacylglycerol synthesis while protecting against fatty acid-induced inflammation and insulin resistance
  302. Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy …
  303. Synthesis of 5-arylidene-2, 4-thiazolidinediones by Knoevenagel condensation catalyzed by baker’s yeast
  304. 3T3‐L1 adipocyte apoptosis induced by thiazolidinediones is peroxisome proliferator‐activated receptor‐γ‐dependent and mediated by the caspase‐3‐dependent …
  305. Substituted thiazolidinediones and thio-imidazolidinones: synthesis, structural study and pharmacological activity.
  306. Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion
  307. Synthesis of new pyrazolyl-2, 4-thiazolidinediones as antibacterial and antifungal agents
  308. Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet
  309. Peroxisome proliferator-activated receptor γ-independent activation of p38 MAPK by thiazolidinediones involves calcium/calmodulin-dependent protein …
  310. Insulin-sensitizing agents–thiazolidinediones (glitazones)
  311. Effects of retinoids and thiazolidinediones on proliferation, insulin release, insulin mRNA, GLUT 2 transporter protein and mRNA of INS‐1 cells
  312. Effects of sulfonylureas on peroxisome proliferator-activated receptor γ activity and on glucose uptake by thiazolidinediones
  313. Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro
  314. Synthetic thiazolidinediones: potential antidiabetic compounds
  315. Mechanism for antioxidative effects of thiazolidinediones in pancreatic β-cells
  316. Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes
  317. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones
  318. Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation?
  319. Thiazolidinediones mimic glucose starvation in facilitating Sp1 degradation through the up-regulation of β-transducin repeat-containing protein
  320. Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes
  321. Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population
  322. Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin
  323. Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors
  324. Thiazolidinediones downregulate Wnt/β-catenin signaling via multiple mechanisms in breast cancer cells
  325. Chronic and acute effects of thiazolidinediones BM13. 1258 and BM15. 2054 on rat skeletal muscle glucose metabolism
  326. Thiazolidinediones and hepatic fibrosis: don’t wait too long
  327. The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II
  328. Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)
  329. Thiazolidinediones, dyslipidaemia and insulin resistance syndrome
  330. A selective peroxisome proliferator-activated receptor-γ modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones
  331. PEROXISOME PROLIFERATOR‐ACTIVATED RECEPTOR γ‐INDEPENDENT EFFECTS OF THIAZOLIDINEDIONES ON HUMAN CARDIAC MYOFIBROBLAST …
  332. Effect of thiazolidinediones on expression of UCP2 and adipocyte markers in human PAZ6 adipocytes
  333. Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor γ for monocyte recruitment and endothelial regeneration
  334. Thiazolidinediones for NASH—one pill doesn’t fix everything
  335. Thiazolidinediones as a novel class of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors
  336. Cost‐Effectiveness Analysis of Thiazolidinediones in Uncontrolled Type 2 Diabetic Patients Receiving Sulfonylureas and Metformin in Thailand
  337. The effects of thiazolidinediones on metabolic complications and lipodystrophy in HIV-infected patients
  338. Thiazolidinediones and bone fractures
  339. Thiazolidinediones are novel insulin-sensitizing agents
  340. Peroxisome proliferator-activated receptor γ-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells
  341. Regulation of glyceroneogenesis and phosphoenolpyruvate carboxykinase by fatty acids, retinoic acids and thiazolidinediones: potential relevance to type 2 diabetes
  342. Thiazolidinediones in patients with diabetes mellitus and heart failure: implications of emerging data
  343. Antagonistic effects of thiazolidinediones and cytokines in lipotoxicity
  344. Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease
  345. Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions
  346. Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells
  347. Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: a meta-analysis of randomized controlled trials
  348. Thiazolidinediones—improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes
  349. Cellular and molecular effects of thiazolidinediones on bone cells: a review
  350. Differential effects of peroxisome proliferator activated receptor-γ (PPARγ) ligands in proximal tubular cells: Thiazolidinediones are partial PPARγ agonists
  351. Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats
  352. Synthesis and biological evaluation of novel pyrazolyl-2, 4-thiazolidinediones as anti-inflammatory and neuroprotective agents
  353. Thiazolidinediones are potent inducers of fibroblast growth factor 21 expression in the liver
  354. Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells
  355. Thiazolidinediones, deadly sins, surrogates, and elephants
  356. Interaction of thiazolidinediones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein
  357. Effect of thiazolidinediones on high-density lipoprotein subfractions
  358. The anti-atherogenic effects of thiazolidinediones
  359. Stimulation of resorption in cultured mouse calvarial bones by thiazolidinediones
  360. Clinical use of thiazolidinediones: recommendations
  361. Effects of thiazolidinediones on glucocorticoid-induced insulin resistance and GLUT4 glucose transporter expression in rat skeletal muscle
  362. Do thiazolidinediones cause congestive heart failure?
  363. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical …
  364. Thiazolidinediones enhance vascular endothelial growth factor expression and induce cell growth inhibition in non-small-cell lung cancer cells
  365. Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle
  366. Thiazolidinediones: a new class of drugs for the therapy of ischemia-reperfusion injury.
  367. Clinical trials with thiazolidinediones in subjects with Type 2 diabetes–is pioglitazone any different from rosiglitazone?
  368. Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARγ-independent mechanism
  369. Nonhypoglycemic effects of thiazolidinediones
  370. Thiazolidinediones and fluid retention
  371. An overview of the beneficial cardiovascular effects of thiazolidinediones
  372. Synthesis of peptides in aqueous medium. VII. Preparation and use of 2, 5-thiazolidinediones in peptide synthesis
  373. The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case–control …
  374. Thiazolidinediones in prediabetes and early type 2 diabetes: what can be learned about that disease’s pathogenesis
  375. Alteration in expression profiles of a series of diabetes-related genes in db/db mice following treatment with thiazolidinediones
  376. The emerging role of thiazolidinediones in the treatment of diabetes-mellitus and related disorders
  377. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes
  378. Novel benzoxazole 2, 4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships
  379. Cytotoxic effects of statins and thiazolidinediones on meningioma cells
  380. 2, 4-Thiazolidinediones as potent and selective human β3 agonists
  381. The effect of thiazolidinediones on bone mineral density in Chinese older patients with type 2 diabetes
  382. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications
  383. … of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement …
  384. Synthesis and aldose reductase inhibitory activity of 5-arylidene-2, 4-thiazolidinediones
  385. Thiazolidinediones and vascular damage
  386. Thiazolidinediones and the preservation of β‐cell function, cellular proliferation and apoptosis
  387. Can thiazolidinediones delay disease progression in type 2 diabetes?
  388. Use of thiazolidinediones in HIV-infected patients: what have we learned?
  389. Insulin-sensitising agents: beyond thiazolidinediones
  390. Mechanism of action of thiazolidinediones.
  391. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone vs rosiglitazone
  392. Thiazolidinediones Induce Rab7–RILP–MAPK‐Dependent Juxtanuclear Lysosome Aggregation and Reduce Tumor Cell Invasion
  393. Inhibition of TGF-β expression: a novel role for thiazolidinediones to implement renoprotection in diabetes
  394. Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case‐control study
  395. Three-dimensional quantitative structure-activity relationships (3D-QSAR) of antidiabetic thiazolidinediones.
  396. Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones
  397. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors.
  398. Long‐term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes
  399. Thiazolidinediones inhibit REG Iα gene transcription in gastrointestinal cancer cells
  400. Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats
  401. Thiazolidinediones may contribute to the intramyocardial lipid accumulation in diabetic myocardium: effects on cardiac function
  402. Quantitative structure–activity analysis of 5-arylidene-2, 4-thiazolidinediones as aldose reductase inhibitors
  403. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome: impact on metabolic and reproductive abnormalities
  404. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones
  405. C‐reactive protein, its role in inflammation, type 2 diabetes and cardiovascular disease, and the effects of insulin‐sensitizing treatment with thiazolidinediones
  406. Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor γ …
  407. Thiazolidinediones and cardiovascular events in high-risk patients with type-2 diabetes mellitus: a comparison with other oral antidiabetic agents
  408. Thiazolidinediones and insulin: rationale for use and role of combination therapy in type 2 diabetes mellitus
  409. Thiazolidinediones modulate the expression of β-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 …
  410. Differential effects of thiazolidinediones on adipocyte growth and recruitment in Zucker fatty rats
  411. Insights on distinct pathways of thiazolidinediones (PPARγ ligand)‐promoted apoptosis in TRAIL‐sensitive or‐resistant malignant urothelial cells
  412. Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy) benzyl]-2, 4-thiazolidinediones.
  413. Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus
  414. … review and meta‐analysis of controlled trials using carotid intima‐media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinediones
  415. Expression and characterization of recombinant rat acyl-CoA synthetases 1, 4, and 5: selective inhibition by triacsin C and thiazolidinediones
  416. The thiazolidinediones or” glitazones” a treatment option for type 2 diabetes mellitus.
  417. Could thiazolidinediones increase the risk of heart failure in Friedreich’s ataxia patients?
  418. Mechanism of TNFα-induced IL-1α, IL-1β and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones
  419. Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone
  420. Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus
  421. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase γ
  422. Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor γ-independent pathway
  423. … of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: Update regarding the thiazolidinediones
  424. Effects of combination of thiazolidinediones with melatonin in dexamethasone-induced insulin resistance in mice
  425. Targeting insulin resistance and β-cell dysfunction: the role of thiazolidinediones
  426. 15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells
  427. Synthesis and biological activity of [[(heterocycloamino) alkoxy] benzyl]-2, 4-thiazolidinediones as PPARγ agonists
  428. Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in …
  429. Thiazolidinediones and congestive heart failure—exacerbation or new onset of left ventricular dysfunction?
  430. Role of Thiazolidinediones in the Management of Type 2 Diabetes
  431. Thiazolidinediones (PPARγ ligands) increase IRS-1, UCP-2 and C/EBPα expression, but not transdifferentiation, in L6 muscle cells
  432. Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice
  433. Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor γ
  434. Thiazolidinediones: potential link between insulin resistance and cardiovascular disease
  435. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits
  436. Thiazolidinediones inhibit TNF-α-mediated osteoclast differentiation of RAW264. 7 macrophages and mouse bone marrow cells through downregulation of NFATC1
  437. Insulin resistance, adipocyte biology, and thiazolidinediones: a review
  438. BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones.
  439. Short insulin tolerance test can determine the effects of thiazolidinediones treatment in type 2 diabetes
  440. Effect of thiazolidinediones on equilibrative nucleoside transporter-1 in human aortic smooth muscle cells
  441. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study: response to Delea et al.
  442. The use of optical coherence tomography to determine the effect of thiazolidinediones on retinal thickness in patients with type 2 diabetes
  443. Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes
  444. Thiazolidinediones influence plasma steroids of male obese Zucker rats
  445. Skeletal toxicity of thiazolidinediones
  446. Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD)
  447. Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of …
  448. Adiponectin receptor gene expression in human skeletal muscle cells is not regulated by fibrates and thiazolidinediones
  449. Comparison of metformin and thiazolidinediones in the management of polycystic ovary syndrome
  450. Pyruvate dehydrogenase kinase 4: regulation by thiazolidinediones and implication in glyceroneogenesis in adipose tissue
  451. Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?
  452. Thiazolidinediones and progression of renal disease in patients with diabetes
  453. Thiazolidinediones with thyroid hormone receptor agonistic activity
  454. Thiazolidinediones and cardiovascular outcomes in type 2 diabetes
  455. Capacitative calcium entry contributes to the differential transactivation of the epidermal growth factor receptor in response to thiazolidinediones
  456. NASH and thiazolidinediones: not to be taken lightly
  457. Alteration of vascular reactivity in diabetic human mammary artery and the effects of thiazolidinediones
  458. Thiazolidinediones and diabetic nephropathy: need for a closer examination?
  459. 5-Arylidene-2, 4-thiazolidinediones as inhibitors of protein tyrosine phosphatases
  460. Effect of thiazolidinediones on the erythropoeitic and germinal cells in the male wistar rats
  461. Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat
  462. In vitro aldose reductase inhibitory activity of 5-benzyl-2, 4-thiazolidinediones
  463. Effect of thiazolidinediones on lipid profile
  464. Cardiovascular disease and benefits of thiazolidinediones.
  465. The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysis
  466. Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans
  467. 15-Deoxy-Δ12, 14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle …
  468. Adiponectin-dependent and-independent pathways in insulin-sensitizing and antidiabetic actions of thiazolidinediones
  469. Thiazolidinediones increase arachidonic acid release and subsequent prostanoid production in a peroxisome proliferator-activated receptor γ-independent manner
  470. Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD‐IMPACT) study
  471. Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity …
  472. Pharmacological therapy for non‐alcoholic steatohepatitis: How efficient are thiazolidinediones?
  473. Thiazolidinediones: antidiabetic drugs with cardiovascular effects
  474. Solution-and solid-phase synthesis of peptide-substituted thiazolidinediones as potential PPAR ligands
  475. Why might thiazolidinediones increase exercise capacity in patients with type 2 diabetes?
  476. Thiazolidinediones inhibit MDCK cyst growth through disrupting oriented cell division and apicobasal polarity
  477. Electrophilic α-thiocyanation of chiral and achiral N-acyl imides. A convenient route to 5-substituted and 5, 5-disubstituted 2, 4-thiazolidinediones
  478. The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy
  479. Point: recent long-term clinical studies support an enhanced role for thiazolidinediones in the management of type 2 diabetes
  480. Thiazolidinediones inhibit the growth of PC12 cells both in vitro and in vivo
  481. A meta-analysis on treatment effects of thiazolidinediones for type 2 diabetes mellitus in Asian populations
  482. Thiazolidinediones prevent PDGF-BB-induced CREB depletion in pulmonary artery smooth muscle cells by preventing upregulation of casein kinase 2 α …
  483. Glucocorticoids repress induction by thiazolidinediones, fibrates, and fatty acids of phosphoenolpyruvate carboxykinase gene expression in adipocytes
  484. Cardiovascular effects of thiazolidinediones
  485. Synthesis and structure of substituted bromo and nitrobenzyl benzylidene imidazolidinediones and thiazolidinediones
  486. Thiazolidinediones exhibit different effects on preadipocytes isolated from rat mesenteric fat tissue and cell line 3T3‐L1 cells derived from mice
  487. Evaluation of in vitro aldose redutase inhibitory activity of 5-arylidene-2, 4-thiazolidinediones
  488. Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population‐based cohort …
  489. Osteoprotegerin, thiazolidinediones treatment, and silent myocardial ischemia in type 2 diabetic patients
  490. Thiazolidinediones and cardiovascular disease
  491. Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and …
  492. Synthesis of spirocyclic thiazolidinediones using ring-closing metathesis and one-pot sequential ring-closing/cross metathesis
  493. Synthesis of O-prenylated and O-geranylated derivatives of 5-benzylidene2, 4-thiazolidinediones and evaluation of their free radical scavenging activity as well as …
  494. Diffusion patterns of new anti-diabetic drugs into hospitals in Taiwan: the case of Thiazolidinediones for diabetes
  495. New therapies in diabetes–thiazolidinediones
  496. Impact of the socioeconomic status on the probability of receiving formulary restricted thiazolidinediones (TZDs)
  497. Diabetes and heart failure: the role of thiazolidinediones in managing these partners in crime
  498. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes
  499. Regiospecific reduction of 5-benzylidene-2, 4-thiazolidinediones and 4-oxo-2-thiazolidinethiones using lithium borohydride in pyridine and tetrahydrofuran
  500. Bone metabolism in type 2 diabetes and role of thiazolidinediones
  501. Synthesis of New 3‐(Substituted Phenacyl)‐5‐[3′‐(4H‐4‐oxo‐1‐benzopyran‐2‐yl)‐benzylidene]‐2,4‐thiazolidinediones and their Antimicrobial Activity
  502. Novel PPARγ-dependent and independent effects for thiazolidinediones
  503. Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes
  504. Oral combination therapy with thiazolidinediones in type 2 diabetes.
  505. Type 2 diabetes, psoriasis and thiazolidinediones
  506. Do thiazolidinediones increase the risk of congestive heart failure and cardiovascular death?
  507. Thiazolidinediones et insulino-sensibilité: rôle du récepteur nucléaire PPARγ
  508. Skeletal effects of thiazolidinediones
  509. Durability of glycemic control: a feature of the thiazolidinediones
  510. 3D-QSAR studies on a series of 5-arylidine-2, 4-thiazolidinediones as aldose reductase inhibitors: a self-organizing molecular field analysis approach
  511. Thiazolidinediones increase the number of platelets in immune thrombocytopenic purpura mice via inhibition of phagocytic activity of the reticulo-endothelial system
  512. Statins but not thiazolidinediones attenuate albumin-mediated chemokine production by proximal tubular cells independently of endocytosis
  513. Altering PPARγ ligand selectivity impairs adipogenesis by thiazolidinediones but not hormonal inducers
  514. Synthesis and antihyperglycemic activity of novel 5-(naphthalenylsulfonyl)-2, 4-thiazolidinediones
  515. Synthesis and biological activity of some new flavonyl-2, 4-thiazolidinediones
  516. Thiazolidinediones–a new class of oral antidiabetic drugs
  517. Effects of thiazolidinediones on cardiovascular risk factors
  518. Medicaid managed care: disparities in the use of thiazolidinediones compared with metformin.
  519. Down-regulation of uncoupling protein-3 and-2 by thiazolidinediones in C2C12 myotubes
  520. Cardioprotective effects of thiazolidinediones, peroxisome proliferator-activated receptor-gamma agonists.
  521. Thiazolidinediones: reactivity of the active methylene group
  522. What evidence should guide the use of thiazolidinediones?
  523. Novel euglycemic and hypolipidemic agents. 4. Pyridyl-and quinolinyl-containing thiazolidinediones
  524. Thiazolidinediones: From antioxidant to neurotherapeutic?
  525. Thiazolidinediones–a new class of oral antidiabetics
  526. Thiazolidinediones, a class of anti-diabetic drugs, inhibit Id2 expression through a PPARγ-independent pathway in human aortic smooth muscle cells
  527. Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones
  528. Self-organizing molecular field analysis of 2, 4-thiazolidinediones: A 3D-QSAR model for the development of human PTP1B inhibitors
  529. Thiazolidinediones and the renal and hormonal response to water immersion-induced volume expansion in type 2 diabetes mellitus
  530. Different effects of thiazolidinediones on target vessel revascularization with bare metal stents: a meta-analysis
  531. Synthesis of peptides in aqueous medium. V. Preparation and use of 2, 5-thiazolidinediones (NTA’s). Use of the 13C-H nuclear magnetic resonance signal as …
  532. Information on thiazolidinediones
  533. QSAR study of 5-arylidene-2, 4-thiazolidinediones as aldose reductase inhibitors
  534. Drug class review: Thiazolidinediones
  535. Acute toxicity assessment of new algicides of thiazolidinediones derivatives, TD53 and TD49, using Ulva pertusa Kjellman
  536. Thiazolidinediones and their effect on bone metabolism: a review
  537. Thiazolidinediones and cardiovascular outcomes
  538. Synthesis and antimicrobial activity of chlorobenzyl benzylidene imidazolidinedione derivatives and substituted thiazolidinediones
  539. Thiazolidinediones and lowered HDL cholesterol
  540. Synthesis and aldose reductase inhibitory activity of some new chromonyl-2, 4-thiazolidinediones
  541. Thiazolidinediones in the treatment of managed care patients with type 2 diabetes
  542. Efficient gene regulation by PPARγ and thiazolidinediones in skeletal muscle and heart
  543. 15-Deoxy-Δ12, 14-prostaglandin J2 and thiazolidinediones transactivate epidermal growth factor and platelet-derived growth factor receptors in vascular smooth …
  544. Thiazolidinediones exert different effects on insulin resistance between dexamethasone-treated rats and wistar fatty rats
  545. Current developments in thiazolidinediones
  546. Thiazolidinediones for type 2 diabetes: no evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4
  547. Rosiglitazone, thiazolidinediones and atherosclerosis
  548. Restoration of impaired p38 activation by insulin in insulin resistant skeletal muscle cells treated with thiazolidinediones
  549. Synthesis and hypoglycemic activity of some substituted flavonyl thiazolidinedione derivatives—fifth communication: flavonyl benzyl substituted 2, 4-thiazolidinediones
  550. Are thiazolidinediones good or bad for the heart?
  551. Use of a PPAR gamma-specific monoclonal antibody to demonstrate thiazolidinediones induce PPAR gamma receptor expression in vitro
  552. Increased adipose expression of the uncoupling protein-3 gene by thiazolidinediones in Wistar fatty rats and in cultured adipocytes.
  553. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy
  554. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones
  555. Management of type 2 diabetes mellitus. Role of thiazolidinediones.
  556. Thiazolidinediones and cardiovascular disease: balancing benefit and harm
  557. An overview and comparison of the thiazolidinediones
  558. Thiazolidinediones do not reduce target vessel revascularization in diabetic patients undergoing percutaneous coronary intervention
  559. Regulation of CCAAT/Enhancer Binding Proteinα (C/EBPα) Gene Expression by Thiazolidinediones in 3T3-L1 Adipocytes
  560. Synthesis and antidiabetic activity of some new chromonyl-2, 4-thiazolidinediones
  561. Suspected suppression of the INR by thiazolidinediones: interaction between warfarin and TZDs
  562. Clinical thiazolidinediones as PPARγ ligands with the potential for the prevention of cardiovascular disease in diabetes
  563. Thiazolidinediones inhibit albumin uptake by proximal tubular cells through a mechanism independent of peroxisome proliferator activated receptor gamma
  564. Update on the Safety of Thiazolidinediones
  565. Cardiovascular effects of thiazolidinediones: a review of the literature.
  566. Type 2 diabetes, thiazolidinediones: bad to the bone?
  567. Standardized reversed-phase thin-layer chromatographic study of the lipophilicity of five anti-diabetic thiazolidinediones
  568. Association of diet alone, insulin, sulfonylureas, metformin, and thiazolidinediones with the severity of coronary artery disease in patients with diabetes mellitus
  569. Improving cardiovascular risk–applying evidence‐based medicine to glucose‐lowering therapy with thiazolidinediones in patients with type 2 diabetes
  570. Thiazolidinediones may be effective in the prevention of stent thrombosis with DES
  571. Adiponectin and its response to thiazolidinediones are associated with insulin‐mediated glucose metabolism in type 2 diabetic patients and their first‐degree relatives
  572. … and ERK1/2 mediated PPARγ-independent event involved in the antiproliferative effect of 15-deoxy-Δ12, 14-prostaglandin J2 and thiazolidinediones in breast cancer …
  573. Diabetes mellitus, thiazolidinediones and fractures: an unfinished story
  574. Sitagliptin compared with thiazolidinediones as a third-line oral antihyperglycemic agent in type 2 diabetes mellitus
  575. Closing the gap between clinical research and clinical practice: can outcome studies with thiazolidinediones improve our understanding of type 2 diabetes?
  576. Effects of thiazolidinediones on the triad of type 2 diabetes mellitus, insulin resistance and cardiovascular disease
  577. Thiazolidinediones as PPAR agonists
  578. Rearrangement of oxazolidinethiones to thiazolidinediones or thiazinanediones and their application for the synthesis of chiral allylic ureas and α-methyl-β-amino …
  579. Mass spectrometry of some benzylidene imidazolidinediones and thiazolidinediones. II-chlorobenzyl imidazolidinedione and fluoro or chlorobenzyl thiazolidinedione …
  580. Dicationic ionic liquid mediated synthesis of 5‐arylidine‐2, 4‐thiazolidinediones
  581. Synthesis of Some Novel 5-Substituted Arylidene–2, 4–Thiazolidinediones as Bioactive Agents
  582. c-Fos-driven transcriptional activation of transforming growth factor β-1: inhibition of high glucose-induced promoter activity by thiazolidinediones
  583. Nuclear peroxisome proliferator-activated receptors and thiazolidinediones
  584. Induction of plasminogen activator inhibitor‐1 (PAI‐1) gene expression in adipocytes by thiazolidinediones
  585. Predictors of nonpersistence with thiazolidinediones in patients with type 2 diabetes
  586. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis
  587. Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones
  588. Use of thiazolidinediones does not affect prostate-specific antigen levels in men with diabetes
  589. Thiazolidinediones may not reduce diabetes incidence in type 1 diabetes
  590. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study: response to Karter et al
  591. Clinical indications for thiazolidinediones
  592. Type 2 diabetes, thiazolidinediones, and cardiovascular risk
  593. Conversion of C2C12 myoblast into adipoblast with thiazolidinediones-A possible basis for Intramuscular fat generation in meat animals
  594. Myocardial 15-Epi-lipoxin A4 Generation Provides a New Mechanism for the Immunomodulatory Effects of Statins and Thiazolidinediones
  595. Synthesis and antimicrobial evaluation of some 3-(substituted phenacyl)-5-[4′-(4H-4-oxo-1-benzopyran-2-yl)-benzylidene]-2, 4-thiazolidinediones
  596. Are thiazolidinediones first-line agents?
  597. Summarising the use of thiazolidinediones with insulin
  598. Do thiazolidinediones harm skeletal integrity?
  599. Studies on 4‐thiazolidinones. I. Cleavage of 3‐Phenyl‐2, 4‐thiazolidinediones with benzylamine and hydrazine
  600. Design, synthesis and in vitro evaluation of a series thiazolidinediones analogs as PPAR modulators
  601. Drug Class Review: Thiazolidinediones: Final Report Update 1
  602. … metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinediones
  603. The potentially inappropriate prescription of new drug: thiazolidinediones for patients with type II diabetes in Taiwan
  604. Chiral N-(o-aryl)-thiazolidinediones: Synthesis from rhodanines and investigation on rotational enantiomers by NMR spectroscopy
  605. Cardiovascular risk-benefit ratio of thiazolidinediones
  606. Novel euglycemic and hypolipidemic agents: pyridine containing unsaturated thiazolidinediones
  607. CoMFA and CoMSIA analysis of 2, 4-thiazolidinediones derivatives as aldose reductase inhibitors
  608. Thiazolidinediones for dementia and mild cognitive impairment
  609. Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones
  610. Thiazolidinediones in type 2 diabetes–have they lived up to expectations?
  611. Thiazolidinediones anti-inflammatory and anti-atherosclerotic effects in type 2 diabetes mellitus
  612. Thiazolidinediones alter growth and epithelial cell integrity, independent of PPAR-γ and MAPK activation, in mouse M1 cortical collecting duct cells
  613. Receptor-independent metabolic effects of thiazolidinediones in astrocytes
  614. Bypassing the side effects of thiazolidinediones?
  615. Thiazolidinediones could improve endothelial dysfunction and risk of premature coronary heart disease in HIV-infected patients
  616. Elevated vitamin D status in postmenopausal women on thiazolidinediones for type 2 diabetes
  617. Studies on 4-thiazolidinones. IX, The conversion of 5-substituted 2-thioxo-4-thiazolidinones into corresponding 2, 4-thiazolidinediones
  618. Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome
  619. Synthesis of N-substituted 2, 4-thiazolidinediones from oxazolidinethiones
  620. 4‐Thiazolidinones and 2, 4‐thiazolidinediones from α‐mercaptopropionic acid and carbodiimides
  621. 5-Aralkylidene-3-isobutyl-2, 4-thiazolidinediones
  622. Tissue triglyceride levels in type 2 diabetes and the role of thiazolidinediones in reversing the effects of tissue hypertriglyceridemia: review of the evidence in animals …
  623. One-Pot Multicomponent Synthetic Route for New Quinolidinyl 2, 4-Thiazolidinediones
  624. An observational study of the effect of two thiazolidinediones on blood lipid levels: Rosiglitazone and pioglitazone in routine clinical practice
  625. The effect of thiazolidinediones on HDL subfractions
  626. Ionic liquid-accelerated N-arylation of 5-arylidene-2, 4-thiazolidinediones with diaryliodonium salts
  627. Clinical difference between thiazolidinediones and biguanides
  628. Regulation of uncoupling protein-2 mRNA in L6 myotubules: I: Thiazolidinediones stimulate uncoupling protein-2 gene expression by a mechanism requiring ongoing …
  629. The transcription factor Fos-related antigen 1 is induced by thiazolidinediones during differentiation of 3T3-L1 cells
  630. Thiazolidinediones as potent inducers of hepatocyte growth factor
  631. Thiazolidinediones and the risk of nontraumatic fractures in patients with diabetes
  632. Effect of thiazolidinediones on insulin resistance and cardiovascular risk factors
  633. Synthesis and antidiabetic activity of some new furochromonyl-2, 4-thiazolidinediones
  634. Thiazolidinediones and salivary gland enlargement
  635. Expression of uncoupling protein-3 mRNA in rat skeletal muscle is acutely stimulated by thiazolidinediones: an exercise-like effect?
  636. Management of type 2 diabetes with thiazolidinediones: link between β-cell preservation and durability of response
  637. Macular edema and thiazolidinediones
  638. On the Reactivity of the Exocyclic Double Bond in 5-Arylidene-3-aryl-2, 4-thiazolidinediones; Their Reaction with Diazoalkanes, p-Thiocresol and Piperidine
  639. Thiazolidinediones associated with recurrent pleural effusions post coronary artery bypass surgery
  640. In vitro aldose reductase inhibitory activity of some flavonyl-2, 4-thiazolidinediones
  641. Mass Spectrometry of Some Benzylidene Imidazolidinediones and Thiazolidinediones. III-Positive and Negative Electron Impact Mass Spectra of Chlorobenzyl …
  642. Thiazolidinediones and PPARgamma system in repair of liver damage
  643. Thiazolidinediones for elderly patients with Type 2 diabetes: safe or not?
  644. Thiazolidinediones for Diabetes Mellitus: Considerations for Reimbursements by Third-Party Payors
  645. Enhancing insulin action: From chemical elements to thiazolidinediones
  646. Thiazolidinediones increased risk for heart failure, myocardial infarction, and death in older patients with type 2 diabetes
  647. Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones.
  648. The thiazolidinediones: a new class of antidiabetic agents
  649. Regulation of MMP-1 expression in vascular endothelial cells by insulin sensitizing thiazolidinediones
  650. Improving management of type 2 diabetes mellitus: 5. Thiazolidinediones
  651. Type 2 Diabetes: Uses of thiazolidinediones and insulin
  652. Thiazolidinediones and cardiovascular risk: Will the evidence so far available modify treatment strategies for type 2 diabetes?
  653. Thiazolidinediones in cardiovascular risk in type 2 diabetes mellitus
  654. Effect of aspirin use on thiazolidinediones and cardiovascular events
  655. Fractures, heart failure and fears of myocardial ischaemia: has the RECORD stuck for rosiglitazone and the thiazolidinediones?
  656. Combination therapy of angiotensin receptor blocker with statin or thiazolidinediones as promising therapeutic strategy for metabolic syndrome and …
  657. The effect of PPAR gamma agonists thiazolidinediones on eosinophil function
  658. Thiazolidinediones and the risk of nontraumatic fractures in patients with diabetes: in reply
  659. Thiazolidinediones could be an effective treatment for HIV-associated progressive multifocal leukoencephalopathy
  660. Risk of heart failure with the use of thiazolidinediones within a medicaid population
  661. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes
  662. Thiazolidinediones increase fracture risk
  663. American Diabetes Association 60th Scientific Sessions, 2000: thiazolidinediones, obesity, and related topics
  664. How beneficial are thiazolidinediones for diabetes mellitus?
  665. … Reagents. XXII. Action of Organomagnesium Compounds on 2-Mercapto-4-arylidene-5-thiazolidones and on 4-Arylidene-2, 5-thiazolidinediones. Reaction of 2 …
  666. Detrimental action of thiazolidinediones on bone
  667. Mass Spectrometry of Some Bromophenacyl Thiothiazolidinones and Thiazolidinediones
  668. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population
  669. Implication for thiazolidinediones (TZDs) as novel potential anti-inflammatory drugs
  670. The place of thiazolidinediones in the treatment of type 2 diabetes
  671. Substituted thiazolidinediones and thioxothiazolidinones: synthesis and structure
  672. Effect of thiazolidinediones (TZDs) on endothelial cell growth and secretion of endothelium-derived vasoactive substances-potential protective action of TZDs on …
  673. Unravelling the antidiabetic mechanisms of the thiazolidinediones
  674. Thiazolidinediones and slowing the progression of diabetes.
  675. Thiazolidinediones in peritoneal dialysis patients
  676. Effects of thiazolidinediones on serum lipoproteins
  677. The effects of thiazolidinediones on blood pressure control among different populations–a meta-analysis
  678. Thiazolidinediones are not associated with increased risk of heart failure hospitalizations in ambulatory patients with diabetes mellitus and heart failure
  679. Dyslipidemia in type 2 diabetes and the effects of thiazolidinediones
  680. Association between the use of thiazolidinediones and the risk of cancer in diabetic patients
  681. Activation of PPAR [Gamma] Inhibits Macrophage Proliferation and Migration: Possible Therapeutic Effectiveness of Thiazolidinediones on Diabetic Vascular …
  682. Thiazolidinediones in NASH An Odd Couple Meant To Be?
  683. What is the future of thiazolidinediones (TZDs) after market introduction of inhaled insulin?
  684. Substituted imidazolidinediones and thiazolidinediones: synthesis, structure and cytotoxic activity
  685. Combination of nateglinide with thiazolidinediones in Type 2 diabetes
  686. Evaluation of Thiazolidinediones on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus: A Systematic Review
  687. Are thiazolidinediones associated with an increased risk of heart failure and cardiovascular death?
  688. Modulation of cardiac fibroblast function by thiazolidinediones with a focus on the role of LOX-1.
  689. Current management of type 2 diabetes: Why thiazolidinediones should be the cornerstone of therapy
  690. Thiazolidinediones
  691. Synthesis and antifungal activity of chlorobenzyl benzylidene thiazolidinediones and substituted of imidazolidinediones
  692. The impact of thiazolidinediones on microalbuminuria in adults with type 2 diabetes mellitus: a systematic review
  693. Thiazolidinediones regulate expression of proteins involved in triglyceride storage and fatty acid oxidation in 3T3-L1 pre-adipocytes
  694. Thiazolidinediones in heart failure: slippery when wet
  695. A Retrospective Review of Thiazolidinediones with Development of a Troglitazone Conversion Protocol
  696. Synthesis and antihyperglycemic activity of novel flavonyl 2, 4-thiazolidinediones
  697. Possible vascular-protective effects of antidiabetic agents such as the thiazolidinediones (TZDs).
  698. Insulinotropic activity of chromonyl-2, 4-thiazolidinediones
  699. Thiazolidinediones exert a hypotriglyceridemic effect by a distinct, but complementary mechanism relative to fibrates
  700. Synthesis of polymeric thiazolidinediones and L-ascorbic acid towards the development of insulin-sensitizer
  701. SYNTHESIS AND EVALUATION OF NEWER QUINOLINE DERIVATIVES OF THIAZOLIDINEDIONES FOR THEIR ANTIDIABETIC ACTIVITY L. SRIKANTH, N …
  702. Organic reactions in ionic liquids: ionic liquid-accelerated facile synthesis of 3-alkyl-2, 4-thiazolidinediones
  703. Drugs for diabetes: Part 3 thiazolidinediones
  704. Antioxidative activities of thiazolidinediones and dihydropyridine-type calcium antagonists
  705. Thiazolidinediones and the Risk of Incident Congestive Heart Failure Among Patients With Type 2 Diabetes Mellitus: A Population-Based Nested Case-Control Study
  706. Information on thiazolidinediones
  707. Trends in management of type 2 diabetes: role of thiazolidinediones
  708. Thiazolidinediones—the Ongoing Debate
  709. … of uncoupling protein-2 mRNA in L6 myotubules: II: thyroid hormone amplifies stimulation of uncoupling protein-2 gene by thiazolidinediones and other peroxisome …
  710. Opposite effects of two thiazolidinediones, ciglitazone and troglitazone, on proteinase-activated receptor-1-triggered prostaglandin E2 release
  711. Comparative study of thiazolidinediones in clinical use
  712. Recent trends in PPARgamma agonist development of thiazolidinediones and non-thiazolidinediones
  713. Thiazolidinediones: a long way to clinical practice
  714. Thiazolidinediones and Bone
  715. Proper usage of thiazolidinediones
  716. Thiazolidinediones.(Medication Update)
  717. Effects of Thiazolidinediones on Coronary Artery Disease
  718. ADOPT: evidence for early use of thiazolidinediones
  719. Thiazolidinediones and type 2 diabetes
  720. Cardiovascular side effects of thiazolidinediones
  721. Thiazolidinediones and insulin resistance
  722. Potential Cardiovascular Effects Of Thiazolidinediones
  723. Effect of Thiazolidinediones on Glycemia
  724. The Truth about Lipid Effects of the Thiazolidinediones
  725. No increase in HF risk or mortality with thiazolidinediones
  726. Role of insulin resistance with the evidence from thiazolidinediones
  727. Thiazolidinediones: Cardiovascular friend or foe
  728. Impact of thiazolidinediones on cardiovascular disease risk factors
  729. Breaking insulin resistance with thiazolidinediones
  730. Drug Class Review: Thiazolidinediones
  731. Thiazolidinediones may increase risk of heart failure
  732. Thiazolidinediones increase fracture risk in both sexes
  733. Thiazolidinediones and reduced bone density
  734. Synthetic use of the ribosyl derivatives of 2, 4-and 2, 5-thiazolidinediones
  735. Do thiazolidinediones increase the risk of cardiovascular events?
  736. Thiazolidinediones–Emerging Evidence on Bone Formation
  737. Thiazolidinediones Appear Safe for Diabetic Eyes
  738. Metformin and thiazolidinediones
  739. Insulin sensitizer drugs, thiazolidinediones: current state and prospect
  740. The effect of thiazolidinediones on leucocytes in type II diabetic patients
  741. Active pharmaceutical ingredient focus: Thiazolidinediones
  742. Thiazolidinediones associated with increased fracture risk
  743. Thiazolidinediones and cardiovascular outcomes in type 2 diabetes
  744. Obesity, insulin resistance and the implication of thiazolidinediones
  745. Thiazolidinediones in the treatment of type 2 diabetes
  746. Precautions for use and contraindications of thiazolidinediones. A cardiologist opinion
  747. Differences between Thiazolidinediones—Do the Lipid Effects Really Matter?
  748. Rosiglitazone and the thiazolidinediones: A changing context
  749. How about the effect of thiazolidinediones in diabetic nephropathy?
  750. Microwave mediated synthesis and antifungal activity of some 5-benzylidene-2, 4-thiazolidinediones
  751. Macular Edema and Thiazolidinediones—Reply
  752. Thiazolidinediones And Type 2 Diabetes Mellitus Proven And Potential Benefits A Review
  753. Thiazolidinediones in the Treatment of Type 2 Diabetes: A Clinician’s Perspective
  754. Severe Cholestatic Hepatitis caused by Thiazolidinediones
  755. Introduction: the role of the thiazolidinediones in the cardiovascular risk management of type 2 diabetes
  756. Thiazolidinediones inhibit liver regeneration
  757. Heart failure, diabetes and the thiazolidinediones: an unfolding story
  758. REGIOSPECIFIC SYNTHESES OF α-GLUTAMYL PEPTIDES VIA 2, 5-THIAZOLIDINEDIONES. PART III.
  759. Effect of thiazolidinediones on early retinopathy in rats with experimental diabetes
  760. Are Thiazolidinediones Superior to Standard Therapy in the Treatment of Type 2 Diabetes?
  761. THE EFFECTS OF THIAZOLIDINEDIONES ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
  762. Thiazolidinediones Tied to Increased Fracture Risk
  763. Combination of Metformin and Thiazolidinediones in Type 2 Diabetes Mellitus-A Review
  764. Thiazolidinediones and Diabetic Macular Edema: Is There an Association?
  765. The Molecular Mechanisms Underlying the Pro-Inflammatory Actions of Thiazolidinediones (TZDs) in Human Macrophages
  766. Effects of Thiazolidinediones on Vascular Reactivity and Endothelial Dysfunction
  767. Persistence rate with thiazolidinediones compared with other antihyperglycemic agents
  768. Fluid retention with thiazolidinediones in diabetic heart failure
  769. Oral thiazolidinediones increase feed intake and growth in sheep
  770. Molecular characterization of insulin resistance in the adipose tissue and the effects of thiazolidinediones
  771. Thiazolidinediones linked to bone loss in diabetic women
  772. Post-Entry Market Analysis of New Drug for Diabetes: Penetration and Concentration of Thiazolidinediones (TZD)
  773. Association Between Use of Thiazolidinediones and Costs of Heart Failure in Patients with Type 2 Diabetes.
  774. Fracture Risk Spikes With Thiazolidinediones
  775. Thiazolidinediones Improve Asthma Control In Diabetic Asthmatics
  776. Thiazolidinediones combined with metformin in treatment of polycystic ovary syndrome: a systematic review
  777. PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA LIGANDS: THIAZOLIDINEDIONES: 502
  778. Thiazolidinediones as selective algicides against harmful red-tide algae
  779. Pharmaceuticals preparations containing thiazolidinediones for the treatment or prevention of IP-10 mediated diseases.
  780. Oral bisphosphonates improve the bone mineral density in men with diabetes with or without thiazolidinediones
  781. Effect of Thiazolidinediones Administration on Neurochemical Composition of MPG Neurons Related to Erection in OLETF Rat
  782. Divergent Effects of Thiazolidinediones on Glucose Transport and Lipid Metabolism in Human Skeletal Muscle Cells
  783. Thiazolidinediones (TZDs) downregulate Wnt/β-catenin signaling via multiple mechanisms in breast cancer cells
  784. Meta-analysis of the Effect of Thiazolidinediones on Restenosis After Coronary Artery Stenting in Patients with or Without Diabetes Mellitus
  785. Do Thiazolidinediones or Statins Suppress Post-Cardiothoracic Surgery Atrial Fibrillation in Diabetics?
  786. Unraveling the effects of Thiazolidinediones and peroxisome proliferator-activated receptor gamma 1 on ovarian cancer
  787. Thiazolidinediones Inhibit Vasoactive Agent-induced [Ca. sup. 2+] Mobilization and Cell Proliferation in Vascular Smooth Muscle Cells
  788. Thiazolidinediones Alter Lipid Bilayer Properties and Native Voltage-Gated Sodium Channel Function
  789. Glucosamine Induced Insulin Resistance in 3T3L1 Adipocytes is Not Prevented by Thiazolidinediones
  790. Do thiazolidinediones exert their insulin-sensitizing effect through the suppression of free Fatty acids?
  791. The effects of glycemic control and thiazolidinediones on the risk of congestive heart failure among patients with type 2 diabetes
  792. Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro
  793. Thiazolidinediones on Insulin Resistance and Insulin Secretion in Obese Diabetic OLETF Rats
  794. The Anti-proliferative Effects of Thiazolidinediones and Non-steriodal Anti-inflammatory Drugs on Androgen-independent Prostate Cancer
  795. Appropriateness of the use of Thiazolidinediones for the treatment of Type 2 Diabetes Mellitus at the Southern Arizona Veterans Affairs Hospital
  796. The influence of thiazolidinediones on marbling in pigs: in vitro studies of muscle stromal-vascular cells from fetal and young pigs and in vivo studies of growing pigs
  797. Insights on distinct pathways of thiazolidinediones (PPARc ligand)-promoted apoptosis in TRAIL-sensitive or-resistant malignant urothelial cells
  798. Thiazolidinediones Attenuate Epithelial-Mesenchymal Transition And Pro-fibrotic Functions In Human Alveolar Epithelial Cells And Lung Fibroblasts
  799. Type 2 diabetes mellitus: Which place for thiazolidinediones in the therapeutic strategy?
  800. Effects of Thiazolidinediones on CETP/ApoB-100 Double Transgenic Mice Made Obese and Insulin Resistant by High Fat/High Carbohydrate Feeding
  801. Synthesis and evaluation of antitumor activity of 5-[2-(3, 5-diaryl-4, 5-dihydro-pyrazol-1-yl)-2-oxo-ethylidene]-2, 4-thiazolidinediones
  802. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP: Thiazolidinediones and the risk of lung, prostate, and …
  803. Thiazolidinediones (TZDs) Inhibit the Expression of Pro-Angiogenic ELR+ CXC Chemokines in Non-Small Cell Lung Cancer (NSCLC) Cells Via a PPAR-γ …
  804. Thiazolidinediones (PPAR [Gamma] Agonists) but Not PPAR [Alpha] Agonists Rapidly Increase IRS-2 Gene Expression in 3T3-L1 Adipocytes
  805. Thiazolidinediones Regulate Internal Ribosome Entry Site Dependent Translation of Insulin-Like Growth Factor-1 Receptor in Human Aortic Smooth Muscle Cells.
  806. … , Prague, Czech Republic OBJECTIVE: Czech guidelines recommend additional therapy with sulfonylurea, insulin or thiazolidinediones (TZD) after met
  807. Differential regulation of stearoyl-CoA desaturase expression and activity by thiazolidinediones, steroid hormones and fatty acid analogs using the mouse 3T3 …
  808. … congenital partial lipodystrophy without lamin A/C and PPARγ mutations (Köbberling type or variety): A long-term follow-up regarding the efficacy of thiazolidinediones …
  809. Thiazolidinediones (Pioglitazone) Blocks P. gingivalis-and F. nucleatum-, but not E. coli-Lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) Production in …
  810. The effect of thiazolidinediones on lipoprotein metabolism: A double blind randomised placebo controlled trial using stable isotopes to investigate the effect of …
  811. Pathological Gambling Associated with Drug Therapy?: Blood Dyscrasias Associated with Thiazolidinediones: Olanzapine Can Cause Metabolic Problems if Used in …
  812. Investigation of the reactivity and tautomerism of azolidines. 41. Reaction of 5-benzylidene-2, 4-thiazolidinediones with formaldehyde
  813. P2-202 Thiazolidinediones are associated with regression of hepatosteatosis in people with type 2 diabetes: the Edinburgh type 2 diabetes study
  814. 1058 INSIGHTS ON PATHWAYS OF THIAZOLIDINEDIONES-PROMOTED APOPTOSIS IN “TUMOR NECROSIS FACTOR-RELATED APOPTOSIS INDUCING LIGAND …
  815. Regulation of the Uncoupling Protein-3 Gene Expression by Thiazolidinediones
  816. 8 Effects of Thiazolidinediones
  817. Thiazolidinediones: the forgotten diabetes medications
  818. Thiazolidinediones as antidiabetic agents: A critical review
  819. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes
  820. Thiazolidinediones
  821. Thiazolidinediones and PPARγ agonists: time for a reassessment
  822. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials
  823. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier
  824. The current role of thiazolidinediones in diabetes management
  825. Chemotherapy and chemoprevention by thiazolidinediones
  826. Cancer risk for patients using thiazolidinediones for type 2 diabetes: A meta‐analysis
  827. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis
  828. Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials
  829. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta‐analysis
  830. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus
  831. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis
  832. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study
  833. Understanding contemporary use of thiazolidinediones: an analysis from the diabetes collaborative registry
  834. Therapeutic actions of the thiazolidinediones in Alzheimer’s disease
  835. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
  836. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer
  837. An update on the current and emerging use of Thiazolidinediones for type 2 diabetes
  838. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis
  839. A new dawn for the use of thiazolidinediones in cancer therapy
  840. Thiazolidinediones and edema: recent advances in the pathogenesis of thiazolidinediones-induced renal sodium retention
  841. Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review
  842. Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present
  843. Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes
  844. Thiazolidinediones and Parkinson disease: a cohort study
  845. Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: a framework for evaluating stratification using routine clinical and …
  846. Are thiazolidinediones a preferred drug treatment for type 2 diabetes?
  847. An uncatalyzed aldol reaction of thiazolidinediones
  848. Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials
  849. Mitochondrial target of thiazolidinediones
  850. A review on thiazolidinediones and bladder cancer in human studies
  851. The journey of thiazolidinediones as modulators of PPARs for the management of diabetes: a current perspective
  852. The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease
  853. Risk of fracture with thiazolidinediones: an individual patient data meta-analysis
  854. Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND
  855. Thiazolidinediones are associated with a reduced risk of COPD exacerbations
  856. Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism
  857. Site-specific chemical modification of peptide and protein by thiazolidinediones
  858. Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson’s disease
  859. Targeting peroxisome proliferator-activated receptors using thiazolidinediones: strategy for design of novel antidiabetic drugs
  860. Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease
  861. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study
  862. Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors
  863. The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: systematic review and meta‐analysis of observational studies
  864. Risk of fracture with thiazolidinediones: disease or drugs?
  865. Thiazolidinediones: an in–depth study of their synthesis and application to medicinal chemistry in the treatment of diabetes mellitus
  866. Thiazolidinediones partially reverse the metabolic disturbances observed in Bscl2/seipin-deficient mice
  867. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus
  868. Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis
  869. Synthesis, biological evaluation and molecular modeling studies of some novel thiazolidinediones with triazole ring
  870. Novel potential artificial MRSA DNA intercalators: Synthesis and biological evaluation of berberine-derived thiazolidinediones
  871. Thiazolidinediones and the risk of asthma exacerbation among patients with diabetes: a cohort study
  872. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes …
  873. Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials
  874. Variation in association between thiazolidinediones and heart failure across ethnic groups: retrospective analysis of large healthcare claims databases in six …
  875. CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes
  876. Ethylenic conjugated coumarin thiazolidinediones as new efficient antimicrobial modulators against clinical methicillin-resistant Staphylococcus aureus
  877. SP1-independent inhibition of FOXM1 by modified thiazolidinediones
  878. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women …
  879. … thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones
  880. Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis
  881. Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis
  882. Thiazolidinediones attenuate lipolysis and ameliorate dexamethasone-induced insulin resistance
  883. Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients
  884. Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties
  885. Thiazolidinediones are associated with a decreased risk of atrial fibrillation compared with other antidiabetic treatment: a nationwide cohort study
  886. The role of thiazolidinediones in hepatocellular carcinoma risk reduction: a population-based cohort study in Taiwan
  887. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists
  888. Effects of three thiazolidinediones on metabolic regulation and cold-induced thermogenesis
  889. The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes
  890. Association between colorectal cancer and thiazolidinediones administration in a case-control study
  891. Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: In-silico studies, synthesis, and biological evaluation
  892. Methylene thiazolidinediones as alkylation reagents in catalytic C–H functionalization: Rapid access to glitazones
  893. Increased circulating adiponectin in response to thiazolidinediones: investigating the role of bone marrow adipose tissue
  894. Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?
  895. Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B
  896. Thiazolidinediones improve flow-mediated dilation: a meta-analysis of randomized clinical trials
  897. Risk of bias in systematic reviews of non-randomized studies of adverse cardiovascular effects of thiazolidinediones and cyclooxygenase-2 inhibitors …
  898. Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study
  899. Deciphering the roles of thiazolidinediones and PPARγ in bladder cancer
  900. Antidiabetic drugs for Alzheimer’s and Parkinson’s diseases: Repurposing insulin, metformin, and thiazolidinediones
  901. Thiazolidinediones promote axonal growth through the activation of the JNK pathway
  902. Capsaicin up-regulates pro-apoptotic activity of thiazolidinediones in glioblastoma cell line
  903. Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer
  904. Pharmacological strategies for insulin sensitivity in obesity and cancer: thiazolidinediones and metformin
  905. Effects of Thiazolidinediones on metabolism and cancer: Relative influence of PPARγ and IGF-1 signaling
  906. Synthesis and structure–activity-relationship studies of thiazolidinediones as antiplasmodial inhibitors of the Plasmodium falciparum cysteine protease falcipain-2
  907. Thiazolidinediones abrogate cervical cancer growth
  908. Effects of first-line diabetes therapy with biguanides, sulphonylurea and thiazolidinediones on the differentiation, proliferation and apoptosis of islet cell …
  909. The direct effect of lobeglitazone, a new thiazolidinedione, on pancreatic beta cells: a comparison with other thiazolidinediones
  910. Mechanistic insights into the augmented effect of bone marrow mesenchymal stem cells and thiazolidinediones in streptozotocin-nicotinamide induced …
  911. Thiazolidinediones and Glucagon‐Like Peptide‐1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study
  912. Thiazolidinediones and risk of atrial fibrillation among patients with diabetes and coronary disease
  913. Synthesis of Chiral Hydantoins and Thiazolidinediones via Iridium‐Catalyzed Asymmetric Hydrogenation
  914. Use of thiazolidinediones and the risk of elective hip or knee replacement: a population based case–control study
  915. PPARγ-Independent side effects of thiazolidinediones on mitochondrial redox state in rat isolated hearts
  916. Design, synthesis, biological evaluation and molecular modelling studies of novel diaryl substituted pyrazolyl thiazolidinediones as potent pancreatic lipase inhibitors
  917. The rise and fall of the thiazolidinediones: impact of clinical evidence publication and formulary change on the prescription incidence of thiazolidinediones
  918. The role of thiazolidinediones in the amelioration of nonalcoholic fatty liver disease: a systematic review
  919. Use of thiazolidinediones and risk of hip fracture in old people in a case–control study in Taiwan
  920. Identification of oxazolidinediones and thiazolidinediones as potent 17β-hydroxysteroid dehydrogenase type 3 inhibitors
  921. Association of hepatocellular carcinoma with thiazolidinediones use: A population-based case-control study
  922. Thiazolidinediones in the treatment of HIV/HAART-associated lipodystrophy syndrome
  923. Design, synthesis, and molecular docking studies of thiazolidinediones as PPAR‐γ agonists and thymidylate synthase inhibitors
  924. New thiazolidinediones affect endothelial cell activation and angiogenesis
  925. Double-edged swords: diaryl pyrazoline thiazolidinediones synchronously targeting cancer epigenetics and angiogenesis
  926. Use of thiazolidinediones and risk of bladder cancer: disease or drugs?
  927. Synthesis and antihyperglycemic evaluation of new 2, 4-thiazolidinediones having biodynamic aryl sulfonylurea moieties
  928. Benzylidene thiazolidinediones: synthesis, in vitro investigations of antiproliferative mechanisms and in vivo efficacy determination in combination with Imatinib
  929. Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes
  930. In search of the neuroprotective mechanism of thiazolidinediones in Parkinson’s disease
  931. Combination therapies with thiazolidinediones are associated with a lower risk of acute exacerbations in new-onset COPD patients with advanced diabetic …
  932. Antifibrotic effects of the thiazolidinediones in eosinophilic esophagitis pathologic remodeling: a preclinical evaluation
  933. Binding of thiazolidinediones to the endoplasmic reticulum protein nutrient-deprivation autophagy factor-1
  934. Density Functional Study on the Cytochrome-Mediated S-Oxidation: Identification of Crucial Reactive Intermediate on the Metabolic Path of Thiazolidinediones
  935. Thiazolidinediones play a positive role in the vascular endothelium and inhibit plaque progression in diabetic patients with coronary atherosclerosis: A …
  936. Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones
  937. PPARγ-independent activity of thiazolidinediones: a promising mechanism of action for new anticancer drugs?
  938. Sensitivity and precision of adverse effects search filters in MEDLINE and EMBASE: a case study of fractures with thiazolidinediones
  939. Lack of longitudinal association between thiazolidinediones and incidence and progression of diabetic eye disease: the ACCORD eye study
  940. Novel N-phenyl–substituted thiazolidinediones protect neural cells against glutamate-and tBid-induced toxicity
  941. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system …
  942. Thiazolidinediones as novel upstream therapy for atrial fibrillation in diabetic patients: a review of current evidence
  943. A novel thiazolidinediones ATZD2 rescues memory deficits in a rat model of type 2 diabetes through antioxidant and antiinflammation
  944. Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis
  945. AMP-activated protein kinase mediates the antiplatelet effects of the thiazolidinediones rosiglitazone and pioglitazone
  946. Thiazolidinediones (TZDs)
  947. Metabonomic profiling revealed an alteration in purine nucleotide metabolism associated with cardiac hypertrophy in rats treated with thiazolidinediones
  948. Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan
  949. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones
  950. Thiazolidinediones improve hepatic fibrosis in rats with non‐alcoholic steatohepatitis by activating the adenosine monophosphate‐activated protein kinase signalling …
  951. Statins, fibrates, thiazolidinediones and resveratrol as adjunctive therapies in sepsis: could mitochondria be a common target?
  952. Structure–activity analysis of harmful algae inhibition by congeneric compounds: case studies of fatty acids and thiazolidinediones
  953. Reversible inhibition of vasoconstriction by thiazolidinediones related to PI3K/Akt inhibition in vascular smooth muscle cells
  954. GIPR expression is induced by thiazolidinediones in a PPARγ-independent manner and repressed by obesogenic stimuli
  955. How Did Multiple FDA actions affect the utilization and reimbursed costs of thiazolidinediones in US medicaid?
  956. Association of the Pro12Ala gene polymorphism with treatment response to thiazolidinediones in patients with type 2 diabetes: a meta-analysis
  957. Thiazolidinediones protect mouse pancreatic β-cells directly from cytokine-induced cytotoxicity through PPARγ-dependent mechanisms
  958. The medicinal perspective of 2, 4‐thiazolidinediones based ligands as antimicrobial, antitumor and antidiabetic agents: A review
  959. The impact of thiazolidinediones on the risk for prostate cancer in patients with type 2 diabetes mellitus: a review and meta-analysis
  960. Antitumor effects of energy restriction-mimetic agents: thiazolidinediones
  961. Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks
  962. Homology modeling and explicit membrane molecular dynamics simulation to delineate the mode of binding of thiazolidinediones into FFAR1 and the mechanism of …
  963. Biphenyl tetrazole-thiazolidinediones as novel bacterial peptide deformylase inhibitors: synthesis, biological evaluations and molecular docking study
  964. Different sites of actions make different responses to thiazolidinediones between mouse and rat models of fatty liver
  965. Upregulation of hepatic LRP1 by rosiglitazone: a possible novel mechanism of the beneficial effect of thiazolidinediones on atherogenic dyslipidemia
  966. Discovery of rhodanine and thiazolidinediones as novel scaffolds for EGFR inhibition: design, synthesis, analysis and CoMSIA studies
  967. Synthesis, In‐Vitro Evaluation and Molecular Docking Study of N‐Substituted Thiazolidinediones as α‐Glucosidase Inhibitors
  968. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient‐level pooled analysis
  969. Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated with …
  970. Thiazolidinediones and risk of long-term dialysis in diabetic patients with advanced chronic kidney disease: a nationwide cohort study
  971. Therapeutic journey of 2, 4-thiazolidinediones as a versatile scaffold: An insight into structure activity relationship
  972. Differential effects of thiazolidinediones and dipeptidyl peptidase-4 inhibitors on insulin resistance and β-cell function in type 2 diabetes mellitus: a propensity …
  973. A new series of 2, 4-thiazolidinediones endowed with potent aldose reductase inhibitory activity
  974. Synthesis, characterization and biological evaluation of some novel 2, 4-thiazolidinediones as potential cytotoxic, antimicrobial and antihyperglycemic agents
  975. Synthesis of New N‐Substituted 5‐Arylidene‐2,4‐thiazolidinediones as Anti‐Inflammatory and Antimicrobial Agents
  976. Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: a meta-analysis
  977. Correlation between PPARG Pro12Ala Polymorphism and Therapeutic Responses to Thiazolidinediones in Patients with Type 2 Diabetes: A Meta-Analysis
  978. PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development
  979. Efficacy and cardiovascular safety of Thiazolidinediones
  980. 2, 4-Thiazolidinediones as PTP 1B Inhibitors: A Mini Review (2012-2018)
  981. Molecular remodeling of the insulin receptor pathway by thiazolidinediones in type 2 diabetes mellitus: A brief review
  982. Thiazolidinediones (TZDs) affect osteoblast viability and biomarkers independently of the TZD effects on aromatase
  983. Apolipoprotein E gene polymorphisms affect the efficacy of thiazolidinediones for Alzheimer’s disease: a systematic review and meta-analysis
  984. Current advances in the biochemical and physiological aspects of the treatment of type 2 diabetes mellitus with thiazolidinediones
  985. … of PPARγ2 in the Heart Determines Differences in Hypertrophic Cardiomyopathy After Treatment With Different Thiazolidinediones in a Mouse Model of …
  986. A solvent-free protocol for the green synthesis of 5-arylidene-2, 4-thiazolidinediones using ethylenediamine diacetate as catalyst
  987. Thiazolidinediones regulate the level of ABC transporters expression on lung cancer cells
  988. Recent pharmacological developments on rhodanines and 2, 4-thiazolidinediones
  989. Impact of thiazolidinediones on macular thickness and volume in diabetic eyes
  990. Antimicrobial activity of thiazolyl benzenesulfonamide-condensed 2, 4-thiazolidinediones derivatives
  991. Synthesis and structure-activity relationship studies of 2, 4-thiazolidinediones and analogous heterocycles as inhibitors of dihydrodipicolinate synthase
  992. Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients
  993. Thiazolidinediones inhibit airway smooth muscle release of the chemokine CXCL10: in vitro comparison with current asthma therapies
  994. Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A …
  995. Long-term therapy with thiazolidinediones and the risk of bladder cancer: A cohort study.
  996. Decreased risk of liver cancer with thiazolidinediones therapy in patients with type 2 diabetes: Results from a meta-analysis
  997. Design, synthesis and biological evaluation of novel 5-(imidazolyl-methyl) thiazolidinediones as antidiabetic agents
  998. Synthesis, HIV-1 RT inhibitory, antibacterial, antifungal and binding mode studies of some novel N-substituted 5-benzylidine-2,4-thiazolidinediones
  999. Benzisoxazole containing thiazolidinediones as peroxisome proliferator activated receptor-γ agonists: design, molecular docking, synthesis & antidiabetic …
  1000. Incretins and thiazolidinediones in glucose homeostasis and cancer: Role of common polymorphisms
  1001. An insight into the synthesis and SAR of 2, 4-thiazolidinediones (2, 4-TZD) as multifunctional scaffold: a review
  1002. Synthesis of some new 2-amino-6-thiocyanato benzothiazole derivatives bearing 2, 4-thiazolidinediones and screening of their in vitro antimicrobial, antitubercular …
  1003. Different effects of thiazolidinediones on in-stent restenosis and target lesion revascularization after PCI: a meta-analysis of randomized controlled trials
  1004. Keratinocyte growth factor and thiazolidinediones and linolenic acid differentiate characterized mammary fat pad adipose stem cells isolated from prepubertal Korean …
  1005. Activation of a retinoic acid receptor pathway by thiazolidinediones induces production of vascular endothelial growth factor/vascular permeability factor in OP9 …
  1006. Treatment with thiazolidinediones
  1007. Polycystic ovarian syndrome: metformin or thiazolidinediones for cardiovascular risk reduction?
  1008. 5-Arylidene (chromenyl-methylene)-thiazolidinediones: potential new agents against mutant oncoproteins K-Ras, N-Ras and B-Raf in colorectal cancer and …
  1009. Comparison of the Effects of Metformin and Thiazolidinediones on Bone Metabolism: A Systematic Review and Meta-Analysis
  1010. Additive effects of omega-3 fatty acids and thiazolidinediones in mice fed a high-fat diet: triacylglycerol/fatty acid cycling in adipose tissue
  1011. Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case–control study
  1012. Thiazolidinediones downregulate PPARγ expression via induction of aP2 during mouse 3T3-L1 preadipocyte differentiation
  1013. Novel 2, 4-thiazolidinediones: Synthesis, in vitro cytotoxic activity, and mechanistic investigation
  1014. The effect of exposure to thiazolidinediones on the development of head-and-neck cancer in patients with diabetes mellitus
  1015. Synthesis, biological evaluation and molecular docking studies of novel 3, 5-disubstituted 2, 4-thiazolidinediones derivatives
  1016. Nelfinavir suppresses insulin signaling and nitric oxide production by human aortic endothelial cells: protective effects of thiazolidinediones
  1017. Thiazolidinediones in the treatment of type 2 diabetesmellitus
  1018. … activating receptor gamma–independent attenuation of interleukin 6 and interleukin 8 secretion from primary endometrial stromal cells by thiazolidinediones
  1019. Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta …
  1020. Synthesis and in vitro cytotoxicity evaluation of phenanthrene linked 2, 4-thiazolidinediones as potential anticancer agents
  1021. Hydroxyl ammonium ionic liquid-catalyzed simple and efficient synthesis of 5-arylidene-2, 4-thiazolidinediones under solvent-free conditions
  1022. Synthesis of 5-Alkylidene-2, 4-thiazolidinediones and Rhodanines Promoted by Propylamino-functionalized Nano-structured SBA-15
  1023. Thiazolidinediones and macular edema: comment on “Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 …
  1024. Experimental and theoretical study of substituent effect on 13C NMR chemical shifts of 5-arylidene-2, 4-thiazolidinediones
  1025. Energy restriction mimetic agents to target cancer cells: comparison between 2-deoxyglucose and thiazolidinediones
  1026. Thiazolidinediones Cause Cardiotoxicity via PPARγ-Independent Mechanism
  1027. Thiazolidinediones (TZDs) enhance insulin secretory response via GPR40 and adenylate cyclase (AC)
  1028. Thiazolidinediones as antidiabetic agents-A Review
  1029. Synthesis of newer 5-benzylidene-2, 4-thiazolidinediones as potential antimicrobials
  1030. Clinical effect of thiazolidinediones in subjects with disorders of carbohydrate metabolism in case of polymorphism rs1801282
  1031. Sonochemistry: A good, fast and clean method to promote the synthesis of 5-arylidene-2, 4-thiazolidinediones
  1032. Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes
  1033. Cell cycle synchronisation using thiazolidinediones affects cellular glucose metabolism and enhances the therapeutic effect of 2-deoxyglucose in colon …
  1034. The impact of water molecules on binding affinity of the anti-diabetic thiazolidinediones for catalase: Kinetic and mechanistic approaches
  1035. Nitro-oleic acid protects mice from diet-induced hepatic steatosis and insulin resistance without the adverse side effects of thiazolidinediones
  1036. Effect of thiazolidinediones on adipocytokines and lipid profile in insulin resistant sprague dawley rats
  1037. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe …
  1038. … , Hypoglycaemic, Hypolipidemic and PPAR γ Agonist Activities of 5‐(2‐Alkyl/aryl‐6‐Arylimidazo [2, 1‐b][1, 3, 4] thiadiazol‐5‐yl) methylene‐1, 3‐Thiazolidinediones
  1039. Substituent and solvent effects on intramolecular charge transfer of 5-arylidene-2, 4-thiazolidinediones
  1040. Design and Synthesis of Echitamine-inspired Hybrid Analogues Containing Thiazolidinediones as Potential Pancreatic Lipase Inhibitors
  1041. Development of new 5-(chromene-3-yl) methylene-2, 4-thiazolidinediones as antimicrobial agents
  1042. Decreased risk of Parkinson’s disease in diabetic patients with thiazolidinediones therapy: An exploratory meta-analysis
  1043. Brown Adipose Tissue PPARγ Is Required for the Insulin-Sensitizing Action of Thiazolidinediones
  1044. Comparative efficacy of thiazolidinediones and metformin for polycystic ovary syndrome
  1045. Synthesis of Bioactive Thioxoimidazolidinones, Oxazolidinones, Thioxothiazolidinones, Thiazolidinediones
  1046. Possible Protective Effects of Thiazolidinediones Antidiabetic Drugs in Colorectal Cancer
  1047. Implications of removing rosiglitazone’s black box warning and restricted access program on the uptake of thiazolidinediones and dipeptidyl peptidase-4 inhibitors …
  1048. Thiazolidinediones Inhibit Mouse Osteoblastic MC3T3-E1 Cell Proliferation in Part Through the Wnt Signaling Pathway
  1049. Insilico Activity Prediction of Thiazolidinediones Derivatives
  1050. Effects of thiazolidinediones on cardiovascular events in patients with type 2 diabetes mellitus after drug-eluting stent implantation: a retrospective cohort study using …
  1051. Solid acid TS-1 catalyst: an efficient catalyst in Knoevenagel condensation for the synthesis of 5-arylidene-2, 4-thiazolidinediones/Rhodanines in aqueous medium
  1052. Simultaneous determination of antidiabetic thiazolidinediones using flow through voltammetric sensor
  1053. Glitazones (thiazolidinediones)
  1054. A review on the clinical safety of thiazolidinediones
  1055. DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin–sulfonylurea dual therapy with inadequate …
  1056. Preparation of Mg-doped Ce-Zr solid catalysts and their catalytic potency for the synthesis of 5-arylidene-2, 4-thiazolidinediones via Knoevenagel condensation
  1057. Effect of Thiazolidinediones on Renal Outcomes in Diabetic Patients with Microalbuminuria or Macroalbuminuria-A Systematic Review and Meta-analysis
  1058. Antioxidant activities of some new chromonyl-2, 4-thiazolidinediones and chromonyl-2, 4-imidazolidinediones having chromone cores
  1059. Solvent and substituent effect on intramolecular charge transfer in 5-arylidene-3-substituted-2, 4-thiazolidinediones: Experimental and theoretical study
  1060. Insertion of thiazolidinediones into carbon nanotube
  1061. Thiazolidine, thiazolidinediones, TZD
  1062. Phosphoryl Chloride Mediated Synthesis of 5-Arylidene-2, 4-Thiazolidinediones Derivatives via Aromatic Bisulfite Adducts
  1063. Estimation of plasma glucose and creatinine level in alloxan-induced diabetic wistar rats treated with metformin and thiazolidinediones
  1064. Is thiazolidinediones use a factor in delaying the need for insulin therapy in type 2 patients with diabetes? A population-based cohort study
  1065. Correlation between activation of PPARγ and resistin downregulation in a mouse adipocyte cell line by a series of thiazolidinediones
  1066. ZnO nanobelts: an efficient catalyst for synthesis of 5-arylidine-2, 4-thiazolidinediones and 5-arylidine-Rhodanines
  1067. Effects of rosiglitazone on the cardiovascular profile in postmenopausal women without diabetes mellitus: interplay of thiazolidinediones and hormone therapy
  1068. Cushingoid lipodystrophy can be prevented by thiazolidinediones
  1069. … of anti-diabetic therapy on overweight/obesity and dyslipidemia: traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like …
  1070. Unexpected regio-and stereoselective [4+ 3] cycloaddition reaction of azomethine ylides with benzylidene thiazolidinediones: synthesis of pharmacologically active …
  1071. Synthesis and pharmacological evaluation of 2, 4-thiazolidinediones as antidiabetic agents
  1072. Thiazolidinediones versus metformin on improving abnormal liver enzymes in patients with type 2 diabetes mellitus: A meta-analysis
  1073. Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: A population‐based cohort study
  1074. Thiazolidinediones: A class of pharmacologically important molecules.
  1075. Effect of hyperglycemia and thiazolidinediones on cardiac angiotensin converting enzyme 2 (ACE2) and neprilysin (NEP) in db/db diabetic mice.
  1076. Chemistry and Applications of Functionalized 2, 4‐Thiazolidinediones
  1077. Molecular docking studies of novel arylidene-2, 4-thiazolidinediones as potential aldose reductase inhibitors
  1078. Differential characterization of myogenic satellite cells with linolenic and retinoic acid in the presence of thiazolidinediones from prepubertal Korean black …
  1079. Physiologically Based Pharmacokinetic Modeling and Simulation of Thiazolidinediones in Patients with Hepatic Impairment
  1080. Chemometric study of retention indices of some thiazolidinediones derivatives in two low polarity stationary phases
  1081. Virtual Screening, Docking, Synthesis and Bioactivity Evaluation of Thiazolidinediones as Potential PPARγ Partial Agonists for Preparation of Antidiabetic Agents
  1082. Ability of two new thiazolidinediones to downregulate proinflammatory cytokines in peripheral blood mononuclear cells from children with asthma
  1083. Role of Galactose, Thiazolidinediones, and NEET proteins in Mitochondrial physiology and therapeutic development.
  1084. Deciphering the Roles of Thiazolidinediones and PPAR in Bladder Cancer
  1085. Design, Synthesis and Antidiabetic Evaluation of New Cyanoquinoloxy Benzylidenyl 2, 4-Thiazolidinediones.
  1086. Assorted applications of N-substituted-2, 4-thiazolidinediones in various pathological conditions
  1087. The effect of Thiazolidinediones on the vascular endothelium and plaque in diabetic patients with coronary atherosclerosis: a meta-analysis
  1088. Synthesis and evaluating anti-inflammatory, antibacterial activity of substituted benzylidene thiazolidinediones
  1089. … : efficient, inexpensive and reusable catalysts for the synthesis of pyrazole derivatives with 2-iminothiazolidin-4-one and 2, 4-thiazolidinediones under solvent-free …
  1090. Synthesis of novel 1, 2, 3-triazoles bearing 2, 4 thiazolidinediones conjugates and their biological evaluation
  1091. Adiponectin versus thiazolidinediones and angiotensin receptor blockers
  1092. Thiazolidinediones and Rheumatoid Arthritis: A Retrospective Cohort Study
  1093. Current drug information: Thiazolidinediones associated with increased risk of bladder cancer among adults with type 2 diabetes
  1094. Heterocyclyl linked phenyl containing Thiazolidinediones and its Cyclic analogs as potential novel Antidiabetic agents
  1095. Clinical Management of Nonalcoholic Steatohepatitis (NASH) With the Use of Thiazolidinediones and the Additive Effect of Thiazolidinediones and a GLP-1 …
  1096. Correction: Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the General Practice Research Database and secondary care data
  1097. The Effect of Thiazolidinediones and SGLT-2 Inhibitors on Minerals, VIT. D3, Blood Glucose and Weight Gain in Wistar Rats Induced with Type 2 Diabetes
  1098. Investigation of substituted thiazolidinediones as corrosion inhibitors on different metals in acidic media
  1099. The Spectrum of Thiazolidinediones against Respiratory Tract Pathogenic Bacteria: An In Vitro and In Silico Approach
  1100. … range of diseases (osteoporosis, diabetes, anorexia, cancer) as well as treatments (corticosteroid, radiation, chemotherapy, thiazolidinediones). However, to advance …
  1101. Hypoglycemic and Hypolipidemic Swords: Synthesis and In-vivo Biological Assessment of 5-benzylidene-2, 4-thiazolidinediones
  1102. … of anti-diabetic drugs on risk of fracture in type 2 diabetes mellitus patients: a network meta-analytic synthesis of randomized controlled trials of thiazolidinediones
  1103. The clinical summary of thiazolidinediones in the treatment of T2DM.
  1104. Green Synthesis of 5-Arylidene-2, 4-Thiazolidinediones Over FeAlPO-5 Catalysts
  1105. Effects of Metformin compared to Thiazolidinediones on vascular endothelial function in Polycystic Ovary syndrome: A systematic review
  1106. ROLES OF THIAZOLIDINEDIONES IN TYPE 2 DIABETES MELLITUS TREATMENT AND WEIGHT GAIN
  1107. The effect of diabetes mellitus, insulin, and thiazolidinediones on bone histomorphometry in streptozotocin-induced diabetic postmenopausal wistar rats
  1108. The Use of Thiazolidinediones in Type 2 Diabetic Patients
  1109. Increasing endogenous PPARγ ligands improves insulin sensitivity and protects against diet-induced obesity without side effects of thiazolidinediones
  1110. Are thiazolidinediones effective in the treatment of nonalcoholic steatohepatitis (NASH)?
  1111. Use of thiazolidinediones and risk of bladder cancer: disease or drugs?
  1112. Beneficial Effects of Inhibition of the Mitochondrial Pyruvate Carrier and the Mechanism of Action of Thiazolidinediones
  1113. Exploring off‐target binding of thiazolidinediones and a novel mechanism for restoring insulin sensitivity (854.2)
  1114. Effects of Thiazolidinediones on In-Stent Restenosis: A Review of IVUS Studies
  1115. Thiazolidinediones as selective algicides against harmful algae
  1116. Effects of thiazolidinediones on vascular endothelial function in patients with type 2 diabetes mellitus
  1117. Development of oedema is associated with an improved glycaemic response in patients initiating thiazolidinediones: a MASTERMIND study
  1118. A Retrospective Evaluation of the use of Thiazolidinediones in Patients with Diabetes Mellitus in a Private Hospital in Ras Al Khaimah.
  1119. Comparative efficacy of thiazolidinediones and metformin for polycystic ovary syndrome
  1120. Modulation of visfatin levels by thiazolidinediones in insulin resistant sprague dawley rats
  1121. Substituent effects on chromatographic retention data of 5-arylidene-2, 4-thiazolidinediones in qsar methodology
  1122. Modulation of visfatin levels by thiazolidinediones in insulin resistant sprague dawley rats
  1123. Effect of thiazolidinediones on insulin resistance and reduced-fat liver
  1124. Effect of Thiazolidinediones (Glitazones) groups on Glycemic control and Lipid profile: A Meta-analysis of Randomized Control Trials
  1125. Thiazolidinediones as potential therapeutic agents in atopic eczema
  1126. Thiazolidinediones Promote Axonal Growth through the Activation of the JNK
  1127. In Silico Study on the Interaction of Thiazolidinediones and β-Lactoglobulin by Molecular Dynamics and Docking Approach
  1128. … of diseases (osteoporosis, diabetes, anorexia, cancer) as well as treatments (corticosteroid, radiation, chemotherapy, thiazolidinediones). However, to advance …
  1129. Effect of thiazolidinediones on dislipidemia in patients with metabolic syndrome depending on the gene PPAR-gamma rs1801282 polymorphism
  1130. Influence of esomeprazole on the pharmacodynamic activity of thiazolidinediones (pioglitazone and rosiglitazone) in animal models
  1131. Controlled clinical trial with the combination therapy with metformin, thiazolidinediones, glucagon-like peptide 1 analog in patients with type 2 diabetes and metabolic …
  1132. Clinical Outcomes and Health Care Costs Evaluation of Sulfonamides and Thiazolidinediones Compared with Dipeptidyl Peptidase 4 Inhibitors for the Treatment of …
  1133. Triple Therapy with Dpp4 Inhibitor, Insulin, or Thiazolidinediones and Risks of Cardiovascular Diseases and All-Cause Mortality in Patients with Failed Metformin-SU …
  1134. Thiazolidinediones inhibit airway smooth muscle release of the chemokine CXCL10: in vitro comparison with current asthma therapies
  1135. Thiazolidinediones’ Insulin-Sensitizing Properties Depend on Adiponectin-Mediated Reductions in Certain Ceramide Species
  1136. … between (UCP1-independent) antidiabetic effects (MSDC-0602) and adipogenic and browning-inducing effects (MSDC-0160) of classical thiazolidinediones  …
  1137. Thiazolidinediones augment anticancer effects of gemcitabine on human pancreatic cancer cells through PPARδ activation
  1138. Effect of thiazolidinediones: PPAR [gamma] agonists on hormones secretion by cells of human adrenocortical cancer in vitro
  1139. Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and b-Cell Function in Type 2 Diabetes Mellitus: A …
  1140. Efficacy and Safety of Once-Weekly Semaglutide vs. Sitagliptin as Add-on to Metformin and/or Thiazolidinediones after 56 Weeks in Subjects with Type 2 Diabetes …
  1141. Stratification using gender and body mass index (BMI) can predict side-effect risk in people with Type 2 diabetes initiating thiazolidinediones but not sulphonylureas: a …
  1142. OR14-05 Hepatocyte Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Offsets the Anti-Steatogenic Effects of Thiazolidinediones in Obese Male Mice
  1143. In the article “Incidence of Cardiovascular Events in Which 2 Thiazolidinediones Are Used as Add-on Treatments for Type 2 Diabetes Mellitus in a Taiwanese …
  1144. Synthesis of new 5-(chromene-3-yl) methylene-2, 4-thiazolidinediones
  1145. Synthesis and In-Vitro Anticancer Evaluation of Novel 5-Substituted Thiazolidinediones
  1146. Novel 2, 4-thiazolidinediones: synthesis, in vitro cytotoxic activity, and mechanistic investigation
Related Posts

BIGUANIDE | BIGUANIDES

(Reverses | Reversal Of | Reverse | Reversed) Obesity

Anti-Aging Effects of Flavonoids & Polyphenols

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping